{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:10:47Z","timestamp":1791295847734,"version":"4.1.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2002,6,1]]},"DOI":"10.1093\/aje\/155.11.1045","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T23:00:51Z","timestamp":1027724451000},"page":"1045-1053","source":"Crossref","is-referenced-by-count":83,"title":["Use of a Marginal Structural Model to Determine the Effect of Aspirin on Cardiovascular Mortality in the Physicians' Health Study"],"prefix":"10.1093","volume":"155","author":[{"given":"Nancy R.","family":"Cook","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R.","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles H.","family":"Hennekens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2002,6,1]]},"reference":[{"key":"key\n\t\t\t\t20180126060646_B1","doi-asserted-by":"crossref","unstructured":"Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med1989;321:129\u201335.","DOI":"10.1056\/NEJM198907203210301"},{"key":"key\n\t\t\t\t20180126060646_B2","doi-asserted-by":"crossref","unstructured":"Cairns J, Cohen L, Colton T, et al. Issues in the early termination of the aspirin component of the Physicians' Health Study. Data Monitoring Board of the Physicians' Health Study. Ann Epidemiol1991;1:395\u2013405.","DOI":"10.1016\/1047-2797(91)90009-2"},{"key":"key\n\t\t\t\t20180126060646_B3","doi-asserted-by":"crossref","unstructured":"Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet therapy. BMJ1989;296:320\u201331.","DOI":"10.1136\/bmj.296.6618.320"},{"key":"key\n\t\t\t\t20180126060646_B4","unstructured":"Aspirin for heart patients. FDA Drug Bull1985;15:34\u20136."},{"key":"key\n\t\t\t\t20180126060646_B5","doi-asserted-by":"crossref","unstructured":"Pearl J. Causal diagrams for empirical research. Biometrika1995;82:669\u2013710.","DOI":"10.1093\/biomet\/82.4.702"},{"key":"key\n\t\t\t\t20180126060646_B6","doi-asserted-by":"crossref","unstructured":"Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. Epidemiology1999;10:37\u201348.","DOI":"10.1097\/00001648-199901000-00008"},{"key":"key\n\t\t\t\t20180126060646_B7","doi-asserted-by":"crossref","unstructured":"Rosenbaum PR. The consequences of adjustment for a concomitant variable that has been affected by treatment. J R Stat Soc (A)1984;147:656\u201366.","DOI":"10.2307\/2981697"},{"key":"key\n\t\t\t\t20180126060646_B8","unstructured":"Robins JM. Marginal structural models. 1997 Proceedings of the Section on Bayesian Statistical Science. Alexandria, VA: American Statistical Association, 1998:1\u201310."},{"key":"key\n\t\t\t\t20180126060646_B9","unstructured":"Robins JM. Association, causation, and marginal structural models. Synthese1999;121:151\u201379."},{"key":"key\n\t\t\t\t20180126060646_B10","unstructured":"Robins JM. Marginal structural models versus structural nested models as tools for causal inference. In: Halloran ME, Berry D, eds. Statistical models in epidemiology: the environment and clinical trials. New York, NY: Springer-Verlag, 1999:95\u2013134."},{"key":"key\n\t\t\t\t20180126060646_B11","doi-asserted-by":"crossref","unstructured":"Robins JM, Hernan M, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology2000;11:550\u201360.","DOI":"10.1097\/00001648-200009000-00011"},{"key":"key\n\t\t\t\t20180126060646_B12","doi-asserted-by":"crossref","unstructured":"Hernan M, Brumback B, Robins JM. Marginal structural models to estimate the joint causal effect of nonrandomized treatments. J Am Stat Assoc2001;96:440\u20138.","DOI":"10.1198\/016214501753168154"},{"key":"key\n\t\t\t\t20180126060646_B13","doi-asserted-by":"crossref","unstructured":"Hernan M, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology2000;11:561\u201370.","DOI":"10.1097\/00001648-200009000-00012"},{"key":"key\n\t\t\t\t20180126060646_B14","doi-asserted-by":"crossref","unstructured":"D'Agostino RB, Lee ML, Belanger AJ, et al. Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study. Stat Med1990;9:1501\u201315.","DOI":"10.1002\/sim.4780091214"},{"key":"key\n\t\t\t\t20180126060646_B15","doi-asserted-by":"crossref","unstructured":"Rubin DB. Bayesian inference for causal effects: the role of randomization. Ann Stat1978;6:34\u201358.","DOI":"10.1214\/aos\/1176344064"},{"key":"key\n\t\t\t\t20180126060646_B16","doi-asserted-by":"crossref","unstructured":"Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika1983;70:41\u201355.","DOI":"10.1093\/biomet\/70.1.41"},{"key":"key\n\t\t\t\t20180126060646_B17","unstructured":"Allison PD. Logistic regression using the SAS system. Cary, NC: SAS Institute, Inc, 1999."},{"key":"key\n\t\t\t\t20180126060646_B18","doi-asserted-by":"crossref","unstructured":"Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics1986;42:121\u201330.","DOI":"10.2307\/2531248"},{"key":"key\n\t\t\t\t20180126060646_B19","doi-asserted-by":"crossref","unstructured":"Efron B, Tibshirani RJ. An introduction to the bootstrap. London, United Kingdom: Chapman-Hall, 1993.","DOI":"10.1007\/978-1-4899-4541-9"},{"key":"key\n\t\t\t\t20180126060646_B20","doi-asserted-by":"crossref","unstructured":"Hennekens CH, Eberlein K. A randomized trial of aspirin and beta-carotene among US physicians. Prev Med1985;14:165\u20138.","DOI":"10.1016\/0091-7435(85)90031-3"},{"key":"key\n\t\t\t\t20180126060646_B21","doi-asserted-by":"crossref","unstructured":"Manson JE, Buring JE, Satterfield S, et al. Baseline characteristics of participants in the Physicians' Health Study: a randomized trial of aspirin and beta-carotene in US physicians. Am J Prev Med1991;7:150\u20134.","DOI":"10.1016\/S0749-3797(18)30931-0"},{"key":"key\n\t\t\t\t20180126060646_B22","doi-asserted-by":"crossref","unstructured":"Joffe MM, Hoover DR, Jacobson LP, et al. Estimating the effect of zidovudine on Kaposi's sarcoma from observational data using a rank preserving structural failure-time model. Stat Med1998;17:1073\u2013102.","DOI":"10.1002\/(SICI)1097-0258(19980530)17:10<1073::AID-SIM789>3.0.CO;2-P"},{"key":"key\n\t\t\t\t20180126060646_B23","doi-asserted-by":"crossref","unstructured":"Miettinen OS. The need for randomization in the study of intended effects. Stat Med1983;2:267\u201371.","DOI":"10.1002\/sim.4780020222"},{"key":"key\n\t\t\t\t20180126060646_B24","doi-asserted-by":"crossref","unstructured":"Joffe M. Confounding by indication: the case of calcium channel blockers. Pharmacoepidemiol Drug Safe2000;9:37\u201341.","DOI":"10.1002\/(SICI)1099-1557(200001\/02)9:1<37::AID-PDS471>3.0.CO;2-U"},{"key":"key\n\t\t\t\t20180126060646_B25","doi-asserted-by":"crossref","unstructured":"Mark SD, Robins JM. A method for the analysis of randomized trials with compliance information: an application to the Multiple Risk Factor Intervention Trial. Control Clin Trials1993;14:79\u201397.","DOI":"10.1016\/0197-2456(93)90012-3"},{"key":"key\n\t\t\t\t20180126060646_B26","doi-asserted-by":"crossref","unstructured":"Robins JM, Finkelstein DM. Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics2000;56:779\u201388.","DOI":"10.1111\/j.0006-341X.2000.00779.x"},{"key":"key\n\t\t\t\t20180126060646_B27","doi-asserted-by":"crossref","unstructured":"Mark SD, Robins JM. Estimating the causal effect of smoking cessation in the presence of confounding factors using a rank preserving structural failure time model. Stat Med1993;12:1605\u201328.","DOI":"10.1002\/sim.4780121707"},{"key":"key\n\t\t\t\t20180126060646_B28","doi-asserted-by":"crossref","unstructured":"Witteman JC, D'Agostino RB, Stijnen T, et al. G-estimation of causal effects: isolated systolic hypertension and cardiovascular death in the Framingham Heart Study. Am J Epidemiol1998;148:390\u2013401.","DOI":"10.1093\/oxfordjournals.aje.a009658"},{"key":"key\n\t\t\t\t20180126060646_B29","doi-asserted-by":"crossref","unstructured":"Robins JM, Greenland S, Hu FC. Estimation of the causal effect of a time-varying exposure on the marginal mean of a repeated binary outcome. J Am Stat Assoc1999;94:687\u2013700.","DOI":"10.1080\/01621459.1999.10474168"}],"container-title":["American Journal of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/aje\/article-pdf\/155\/11\/1045\/23664385\/1045.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T09:45:50Z","timestamp":1583315150000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/aje\/article\/155\/11\/1045\/57280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,6,1]]},"references-count":29,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2002,6,1]]},"published-print":{"date-parts":[[2002,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/aje\/155.11.1045","relation":{},"ISSN":["1476-6256","0002-9262"],"issn-type":[{"value":"1476-6256","type":"electronic"},{"value":"0002-9262","type":"print"}],"subject":[],"published-other":{"date-parts":[[2002,6,1]]},"published":{"date-parts":[[2002,6,1]]}}}